BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
297.95
-0.95 (-0.32%)
At close: Apr 28, 2026, 4:00 PM EDT
298.50
+0.56 (0.19%)
After-hours: Apr 28, 2026, 6:02 PM EDT

BeOne Medicines AG Stock Forecast

Stock Price Forecast

The 11 analysts with 12-month price forecasts for BeOne Medicines AG stock have an average target of 380.45, with a low estimate of 290 and a high estimate of 425. The average target predicts an increase of 27.69% from the current stock price of 297.95.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $290 $380.45 $396 $425
Change -2.67% +27.69% +32.91% +42.64%
* Price targets were last updated on Mar 27, 2026.

Analyst Ratings

The average analyst rating for BeOne Medicines AG stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Nov '25Dec '25Jan '26Feb '26Mar '26Apr '26
Strong Buy 444444
Buy 888876
Hold 000011
Sell 000000
Strong Sell 000000
Total 121212121211

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Wolfe Research
Wolfe Research
Buy
Initiates
$340
Buy Initiates $340 +14.12% Mar 27, 2026
Jefferies
Jefferies
Hold
Downgrades
$420$290
Hold Downgrades $420$290 -2.67% Mar 16, 2026
RBC Capital
RBC Capital
Buy
Maintains
$417$425
Buy Maintains $417$425 +42.64% Feb 27, 2026
Truist Securities
Truist Securities
Strong Buy
Maintains
$400$412
Strong Buy Maintains $400$412 +38.28% Feb 27, 2026
Guggenheim
Guggenheim
Strong Buy
Maintains
$400$410
Strong Buy Maintains $400$410 +37.61% Feb 27, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
45.27B
from 5.34B
Increased by 747.23%
Revenue Next Year
52.41B
from 45.27B
Increased by 15.78%
EPS This Year
3.30
from 2.47
Increased by 33.64%
EPS Next Year
4.86
from 3.30
Increased by 47.12%
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
1.18B1.42B2.46B3.81B5.34B45.27B52.41B
Revenue Growth
280.83%20.37%73.65%54.97%40.23%747.23%15.78%
EPS
-15.71-19.43-8.45-6.122.473.304.86
EPS Growth
-----33.64%47.12%
Forward PE
-----90.2661.35
No. Analysts -----99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20262027202820292030203120322033
High 48.6B 59.8B
Avg 45.3B 52.4B
Low 42.0B 46.6B

Revenue Growth

Revenue Growth 20262027202820292030203120322033
High
809.5%
32.2%
Avg
747.2%
15.8%
Low
686.5%
3.0%

EPS Forecast

EPS 20262027202820292030203120322033
High 3.84 7.07
Avg 3.30 4.86
Low 2.90 2.93

EPS Growth

EPS Growth 20262027202820292030203120322033
High
55.6%
114.1%
Avg
33.6%
47.1%
Low
17.4%
-11.2%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.